𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study

✍ Scribed by Jalid Sehouli,Klaus Pietzner,Pauline Wimberger,Ignace Vergote…

Book ID
126363904
Publisher
Springer US
Year
2014
Tongue
English
Weight
328 KB
Volume
31
Category
Article
ISSN
1357-0560

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The trifunctional antibody catumaxomab f
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
✍ Markus M. Heiss; Pawel Murawa; Piotr Koralewski; Elzbieta Kutarska; Olena O. Kol 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 559 KB

## Abstract Malignant ascites is a common manifestation of advanced cancers, and treatment options are limited. The trifunctional antibody catumaxomab (anti‐epithelial cell‐adhesion molecule x anti‐CD3) represents a targeted immunotherapy for the intraperitoneal (i.p.) treatment of malignant ascite